| Literature DB >> 29534031 |
Roger Fielding1, Linda Riede2, James P Lugo3, Aouatef Bellamine4.
Abstract
Given its pivotal role in fatty acid oxidation and energy metabolism, l-carnitine has been investigated as ergogenic aid for enhancing exercise capacity in the healthy athletic population. Early research indicates its beneficial effects on acute physical performance, such as increased maximum oxygen consumption and higher power output. Later studies point to the positive impact of dietary supplementation with l-carnitine on the recovery process after exercise. It is demonstrated that l-carnitine alleviates muscle injury and reduces markers of cellular damage and free radical formation accompanied by attenuation of muscle soreness. The supplementation-based increase in serum and muscle l-carnitine contents is suggested to enhance blood flow and oxygen supply to the muscle tissue via improved endothelial function thereby reducing hypoxia-induced cellular and biochemical disruptions. Studies in older adults further showed that l-carnitine intake can lead to increased muscle mass accompanied by a decrease in body weight and reduced physical and mental fatigue. Based on current animal studies, a role of l-carnitine in the prevention of age-associated muscle protein degradation and regulation of mitochondrial homeostasis is suggested.Entities:
Keywords: ">l-carnitine; aging; exercise recovery; muscle metabolism; physical performance
Mesh:
Substances:
Year: 2018 PMID: 29534031 PMCID: PMC5872767 DOI: 10.3390/nu10030349
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1l-carnitine function. l-carnitine shuttles long-chain fatty acids inside the mitochondria by forming a long chain acetylcarnitine ester. The complex is then transported into the mitochondrial matrix by carnitine palmitoyltransferase I (CPT I) and carnitine palmitoyltransferase II (CPT II). The fatty acids are then broken down through the process of β-oxidation to deliver the 2-carbon molecules to the Krebs cycle, leading to the generation of energy under the form of adenosine triphosphate (ATP). In addition, by binding an acetyl group, l-carnitine can maintain the levels of Acetyl-CoA and coenzyme A, playing its buffering role.
Summary of clinical studies investigating the effect of l-carnitine on exercise performance and recovery.
| Authors/Title | # Subject | Age (Mean or Range) | Dose Duration | Outcome |
|---|---|---|---|---|
| 24 athletes | 19–27 | 1 g BID for 6 mo of training | Prevention of training decreased total and free. | |
| 7 junior athletes | na | 1 g/d for 6 wk and 2 g/d for 10 d (before competition) | Supplemented group showed better stress-induced efforts and obtained higher performances. | |
| 110 athletes (in 6 studies) | 16–33 | 4 g oral of 1 g iv (single dose) | Single dose: beneficial effects on physical output, lipid metabolism, muscular function (contraction), lactate accumulation after exercise and urine mucoproteins. | |
| 14 athletes | na | 2 g BID for 4 wk of training | Increase in respiratory-chain enzyme activities in the muscle. | |
| 26 athletes | 18.42 ± 0.5 | 12 received 3 g | Compared to placebo, | |
| 7 athletes | 36 ± 3 | 2 g before start and after 20 km run | Significant increase in | |
| 9 healthy, previously resistance trained men | 25.2 ± 6 | 2 g/d for 23 d or placebo | Enhanced oxygen consumption => hypoxic stress is attenuated with carnitine supplementation. | |
| 10 resistance-trained men | 22 ± 1 | 2 g/d for 21 d or placebo | Increased androgen receptor content and enhanced luteinizing hormone. | |
| 9 athletes | na | 1 g before and after treadmill ergometer or placebo | No decrease in serum carnitine levels after exercise in the supplementation group. | |
| 15 athletes | Pl: 31 ± 8 | 3 g/d for 15 d or placebo | No significant difference between whole-body rates of CHO and fat oxidation at any workload. At day 15, heart rate and blood glucose concentration were lower during exercise in the | |
| 20 active male athletes | Pl: 32 ± 9 | 2 g/d for 2 wks or placebo | After 2 wk of | |
| 10 moderately trained men | 18.42 ± 0.50 | 2 g before high-intensity exercise | Stimulation of PDH activity, and decrease in plasma | |
| 10 moderately trained men | 22–30 | 2 g before high-intensity exercise | Increased VO2max. | |
| 15 trained males | 20–46 | 3 g for 4 wk or placebo | No effect on substrate utilization or endurance performance. | |
| 6 untrained subjects | 26 ± 3.8 | 3 g/d for 3 wk | Protective effect against pain and damage from eccentric effort. | |
| 10 healthy, recreationally weight-trained men | 23.7 ± 2.3 | 2 g/d for 3 wk | Increased IGFBP-3 concentrations prior to and at 30, 120, and 180 min after acute exercise => protection from muscle damage. | |
| 9 healthy males | 24.9 ± 1.0 | 3 g/d for 7 d | No effects on fat oxidation, RQ, perceived exertion, lactate, heart rate during exercise after glycogen depletion. | |
| 20 (swimmers) | 20.1 ± 0.6 | 2 g BID for 7 d or placebo | Elevation in serum l-carnitine and carnitine fractions. | |
| 8 | 26.8 ± 2.31 | 4 g/d for 14 d | Increase in serum carnitine. | |
| 12 (trained/untrained) | 25.7 ± 4 | 2 g/d for 5 d | Improved recovery in 9 of 12 subjects. | |
| 12 | 25 ± 3 | 2 g/d for 14 d or placebo | 2 g of | |
| 30 healthy subjects | 30 ± 8 | 2 g for 3 wk or placebo | Improvement in postprandial vascular functions after a high-fat meal. | |
| 8 healthy men | 22 ± 3 | 0, 1 g, 2 g for 3 wk | Increase in serum carnitine concentrations. | |
| 30 healthy men and women | 30 ± 8 | 2 g/d for 3 wk or placebo | Improvement in postprandial flow-mediated dilatation after a high-fat meal. | |
| 21 active healthy men | About 22 | 2 g/d for 14 d or placebo | Increase in total antioxidant capacity after 14d and 24h post exercise. | |
| 18 healthy men and women | m: 45.4 ± 5.3 | 2 g/d for 24 d | Positive effects on purine metabolism, free radical formation, muscle tissue disruption, muscle soreness. | |
| 8 healthy male adults | 23–25 | 2 × 2 g/d for 3 months | No significant differences between VO2max, RERmax, and Pmax between the three time points investigated: pre/post at baseline and post exercise after 3 months. | |
| 10 young males | na | 2 g/d for 4 wks; followed by 0 g/d for 6–8 wks | Twenty-five percent increase in free and total L-carnitine plasma levels during supplementation. | |
| 66 centenarians | 100–106 | 2 g/d or placebo for 6 mo | Reduction of total fat mass, increases total muscular mass, and facilitates an increased capacity for physical and cognitive activity by reducing fatigue and improving cognitive functions. | |
| 84 elderly subjects | 81.5 ± 6.7 | 2 g BID for 30 day or placebo | Improvements in the following parameters: total fat mass, total muscle mass, total cholesterol, LDL-C, HDL-C, triglycerides, apoAl, and apoB. | |
| 96 aged subjects | 71–88 | 2 g BID for 180 d or placebo | Reduction in both physical and mental fatigue and improvement of both the cognitive status and physical functions. | |
| 42 healthy older adults | 55–70 | 1.5 g carnitine or carnitine combination or placebo for 8 wk | ||
Abbreviation used: BID: twice per day; d: day; wk: week; mo: month; CHO: carbohydrates; Pl: placebo; LC: l-Carnitine; PDH: pyruvate dehydrogenase; VO2max: maximal oxygen uptake; CK: creatine kinase; IGFBP-3: insulin-like-growth-factor-binding-protein-3; RQ: respiratory quotient; LA: lactate; BE: base excess; TBARS: thiobarbituric acid reactive substances; RERmax: maximal respiratory exchange ratio; Pmax: maximal power; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; apoA1: Apolipoprotein A1; apoB: apolipoprotein B; mTOR: mechanistic target of rapamycin.